he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
- 大咖直播—6 大公益提供援助詳解：國際癲癇關愛日，患者最高可獲 10 萬元手術費用減免
- Circ ep：心電圖空自動診斷可能漏診部分QTc延長者
- 腦梗的癥狀有哪些 有了這些起因要謹慎
- 新版醫保藥品達2800種 “逢進必談”的藥都有哪些？獨自一人來看！
- nus癲癇藥物Trokendi XR已獲FDA股票批準
- 瘙癢癥嚴寒預防措施 瘙癢癥患者嚴寒洗浴要點
- 癲癇病食療方法 傳統醫學民族特色
- 芒果配伍排骨 補腎又養胃
- 使用頭孢 3 天后，患者發生躁狂打碎了監護儀？！這類抗生素腦病值得警惕！
- Medpage Today：不同類別抗癲癇藥物的聯用更十分困難
- Circ ep：心電圖機終端診斷可能漏診部分QTc延長者
- 藥企實驗室（研發/QC）規約管理與 ICH指南及藥典最新進展
- 全「利」控制 升級保護措施——利必通?分散片中國上市會